| Followers | 1438 |
| Posts | 30127 |
| Boards Moderated | 23 |
| Alias Born | 12/10/2012 |
Wednesday, March 19, 2025 10:58:07 AM
$AKBA: Nuttssssssssssssssssssssss
Whats the deal here...... now $2.80
Someone wanna shed some light on this ???
GO $AKBA
Whats the deal here...... now $2.80
Someone wanna shed some light on this ???
GO $AKBA
Recent AKBA News
- Akebia Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of AKB-9090 • GlobeNewswire Inc. • 04/13/2026 12:00:00 PM
- Akebia Therapeutics to Conduct Investor Meetings at the Raymond James 2026 Biotech Innovation Symposium • GlobeNewswire Inc. • 04/07/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/03/2026 08:06:54 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 04/03/2026 08:05:32 PM
- Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 04/02/2026 08:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/01/2026 08:48:09 PM
- Akebia Therapeutics Appoints Biopharmaceutical Leader Philip Vickers, Ph.D. to its Board of Directors • GlobeNewswire Inc. • 04/01/2026 08:05:00 PM
- Akebia Therapeutics to Host Virtual R&D Day Highlighting Robust Kidney Disease Pipeline, on April 2, 2026 • GlobeNewswire Inc. • 03/19/2026 08:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2026 11:55:46 PM
- Akebia Therapeutics to Present at the Leerink Partners 2026 Global Healthcare Conference • GlobeNewswire Inc. • 03/03/2026 01:00:00 PM
- Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 03/02/2026 09:05:00 PM
- Akebia Therapeutics posts mixed Q4 results as revenue beats expectations despite EPS miss • IH Market News • 02/26/2026 03:57:19 PM
- Akebia tops Q4 revenue expectations as Vafseo momentum strengthens outlook • IH Market News • 02/26/2026 03:48:23 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/26/2026 12:04:39 PM
- Akebia Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Commercial and Pipeline Highlights • GlobeNewswire Inc. • 02/26/2026 12:00:00 PM
- Akebia Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Discuss Recent Business Highlights • GlobeNewswire Inc. • 02/19/2026 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 09:15:29 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 09:13:46 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 09:13:17 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 09:12:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 09:11:02 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 09:10:28 PM
- Akebia Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 • GlobeNewswire Inc. • 02/04/2026 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/03/2026 09:42:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/03/2026 09:41:12 PM
